No Data
No Data
Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40
Morgan Stanley analyst Michael Ulz maintains $Kyverna Therapeutics(KYTX.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 43.7
Leerink Partners Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Announces Target Price $48
Leerink Partners analyst Thomas Smith maintains $Kyverna Therapeutics(KYTX.US)$ with a buy rating, and sets the target price at $48.According to TipRanks data, the analyst has a success rate of 47.3%
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
Kyverna Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
HC Wainwright & Co. Reiterates Neutral on Kyverna Therapeutics, Maintains $8 Price Target
Kyverna (KYTX) Sees Pre-Market Surge After Regulatory Milestone
No Data